San Jose, California (PRWEB) September 17, 2013
Follow us on LinkedIn – In the coming months, GIA will complete an extensive secondary and primary research program involving some of the industry’s leading players and experts. The study will examine key drivers and trends impacting the market such as high prevalence of cancer worldwide; unmet medical needs in cancer treatment and diagnosis; strong investments in R&D designed to unlock the untapped potential of circulating cancer biomarkers; and supportive regulatory and reimbursement policies especially in developed countries.
Defined as cells separated from the tumor and circulating in the blood, circulating tumor cells are a primary cause for promoting metastasis. Identification of blood circulating tumor cells is therefore gaining in importance as a diagnostic tool. With the growing body of evidence supporting the view that circulating tumor cells (CTCs) can help predict outcome of cancerous tumors in patients, there is heightened interest in utilizing CTCs in improving prognosis and optimizing treatment choices by accurately predicting response to therapies. Circulating biomarker research is therefore gaining in importance. Circulating, cell-free microRNAs (miRNAs) will emerge as a promising new class of cancer biomarkers with valuable benefits in clinical practice. Molecular characterization of CTCs will aid in limiting metastasis in early stages thus improving the chances of survival. Ongoing technology advances are facilitating development of newer methods for detecting and removing CTCs that cause metastasis from blood. Growing popularity and adoption of personalized cancer medicine will additionally spur R&D efforts in developing tumor-specific biomarkers. The coming years will witness commercial opportunities for CTCs in the area of therapeutic selection and patient monitoring.
Fuelled by the need for more effective treatment options and growing focus of the medical community to develop drugs and therapies that target tumor roots, research in the field of Cancer Stem Cells (CSCs) is attracting increased investments. Stem cells also known as progenitor cells, represent cells that are capable of regenerating malignant tumor cells and thus are responsible for the spread of cancer. As a key cause for tumor recurrence, metastasis, and resistance, cancer stem cells are therefore an important theme for R&D, especially as a drug target. The coming years are forecast to witness the development of novel drugs that target cancer stem cells (CSCs).
In addition to technical growth drivers, key market forces fuelling growth include rising awareness about cancer among the patient base, growing disposable incomes and greater healthcare per capita spends especially in developing countries, establishment of latest healthcare facilities and improvement in quality of care offered, and supportive legislations that encourage R&D investments among big pharma companies by mitigating R&D risk exposure in this space.
The study estimates the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) to be a multi-million dollar market, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.
The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.
Developed for Oncology Drug Developers and Manufacturers, Cancer Diagnostics Companies, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.
For more details about how you can participate, please click here
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
Read the full story at http://www.prweb.com/releases/cancer_stem_cells/circulating_tumor_cells/prweb11130687.htm.
Copyright©2012 Vocus, Inc.
All rights reserved